Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Trial Examining the Impact Of Neoadjuvant Axitinib On Primary Tumor Response In Patients With Locally Advanced Clear Cell Renal Cell Carcinoma

NCT01263769 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT01263769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01263769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Trial Examining the Impact Of Neoadjuvant Axitinib On Primary Tumor Response In Patients With Locally Advanced Clear Cell Renal Cell Carcinoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2011
Completion date
June 5, 2023
Enrollment
39 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer